Force-feeding malignant mesothelioma stem-cell like with exosome-delivered miR-126 induces tumour cell killing

• DOI: 10.1016/j.tranon.2022.101400
• Publication Date: 2022-03-23T03:50:57Z
• Authors: Federica Monaco; Laura De Conti; Simone Vodret; Nunzia Zanotta; Manola Comar; Sandra Manzotti; Corrado Rubini; Laura Graciotti; Gianluca Fulgenzi; Massimo Bovenzi; Marco Baralle; Marco Tomasetti; Lory Santarelli
• Keywords: Mesothelioma; 0303 health sciences; miRNA-based therapy; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; spheroids; miR-126; 3. Good health; 03 medical and health sciences; Mesothelioma; miR-126; exosome; spheroids; miRNA-based therapy; spheroid; exosome; RC254-282; Original Research

Malignant pleural mesothelioma (MPM) is an aggressive tumour resistant to treatments. It has been postulated that cancer stem cells (CSCs) persist in tumours causing relapse after multimodality treatment. In the present study, a novel miRNA-based therapy approach is proposed. MPM-derived spheroids have been treated with exosome-delivered miR-126 (exo-miR) and evaluated for their anticancer effect. The exo-miR treatment increased MPM stem-cell like stemness and inhibited cell proliferation. However, at a prolonged time, the up taken miR-126 was released by the cells themselves through exosomes; the inhibition of exosome release by an exosome release inhibitor GW4869 induced miR-126 intracellular accumulation leading to massive cell death and in vivo tumour growth arrest. Autophagy is involved in these processes; miR-126 accumulation induced a protective autophagy and the inhibition of this process by GW4869 generates a metabolic crisis that promotes necroptosis, which was associated with PARP-1 over-expression and cyt-c and AIF release. Here, for the first time, we proposed a therapy against CSCs, a heterogeneous cell population involved in cancer development and relapse.